SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 - 7 in Chicago. More than 200 abstracts have been accepted across nearly eight cancer types, including four “late breakers” and nearly 30 oral presentations.
